key: cord-1029772-cdt57fec
authors: Fass, E.; Zizelski Valenci, G.; Rubinstein, M.; Freidlin, P. J.; Rosencwaig, S.; Kutikov, I.; Werner, R.; Ben-Tovim, N.; Bucris, E.; Zuckerman, N. S.; Mor, O.; Mendelson, E.; Dveyrin, Z.; Rorman, E.; Nissan, I.
title: HiSpike: A high-throughput cost effective sequencing method for the SARS-CoV-2 spike gene
date: 2021-03-05
journal: nan
DOI: 10.1101/2021.03.02.21252290
sha: 601e6984e97766a04211cb851ae2d8db73a711c0
doc_id: 1029772
cord_uid: cdt57fec

The changing nature of the corona virus of the SARS-CoV-2 pandemic poses unprecedented challenges to the world health systems. New and virulent emerging spike gene variants, such as the UK 20I/501Y.V1 and South African 20H/501Y.V2, could jeopardize global efforts to produce immunity and reduce mortality. These challenges require effective real-time genomic surveillance solutions that the medical community can quickly adopt. The SARS-CoV-2 spike protein mediates host receptor recognition and entry into the cell and therefore, it is most susceptible to generation of variants with increased transmissibility and pathogenicity. The spike protein is also the primary target of neutralizing antibodies in COVID-19 patients and the most common antigen for induction of effective vaccine immunity. Therefore, tight monitoring of the spike protein gene variants is key to mitigating COVID-19 spread and vaccine escape mutants. Currently, the ARTIC method for SARS-CoV-2 whole genome sequencing is applied worldwide. However, this method commonly requires more than 96 hours (4-5 days) from start to finish and at present high sample sequence demands, sequencing resources are quickly exhausted. In this work, we present HiSpike, a method for high-throughput targeted next generation sequencing (NGS) of the spike gene. This simple three-step method can be completed in less than 30 hours and can sequence 10-fold more samples compared to the conventional ARTIC method and at a fraction of the cost. HiSpike was proven valid, and has identified, at high quality, multiple spike variants from real-time field samples, such as the UK and the South African variants. This method will certainly be effective in discovering future spike mutations. Therefore, running HiSpike for full sequencing of the spike gene of all positive SARS-CoV-2 samples could be considered for near real-time detection of known and emerging spike mutations as they evolve. HiSpike provides affordable sequencing options to help laboratories conserve resources, hence it provides a tool for widespread monitoring, that can support critical knowledge-based decisions.

resources are quickly exhausted. In this work, we present HiSpike, a method for highthroughput targeted next generation sequencing (NGS) of the spike gene. This simple three-step method can be completed in less than 30 hours and can sequence 10-fold more samples compared to the conventional ARTIC method and at a fraction of the cost.

HiSpike was proven valid, and has identified, at high quality, multiple spike variants from real-time field samples, such as the UK and the South African variants. This method will certainly be effective in discovering future spike mutations. Therefore, running HiSpike for full sequencing of the spike gene of all positive SARS-CoV-2 samples could be considered for near real-time detection of known and emerging spike mutations as they evolve. HiSpike provides affordable sequencing options to help laboratories conserve resources, hence it provides a tool for widespread monitoring, that can support critical knowledge-based decisions.

Wuhan, China [1] [2] [3] [4] into a worldwide pandemic [5] [6] [7] [8] , inflicting morbidity and mortality on currently over 100 million people with nearly 2.5 million deaths. COVID-19 has severely disrupted health and educational systems, and continues to wreak social, cultural, and economic havoc in afflicted countries.

The spike protein, a homotrimeric class I fusion glycoprotein, is responsible for the ability of the SARS-CoV-2 virus to recognize and bind to the host cell receptor angiotensin converting enzyme 2 (ACE2) [9] [10] [11] [12] [13] [14] , and to induce subsequent membrane fusion and viral entry into the host cell [15, 16] . It is thought that mutation-driven changes to the spike protein promoted the initial zoonotic event of coronavirus jump from animal reservoir to human [17] [18] [19] , and that continued mutation-driven change of SARS-CoV-2 spike protein in COVID-19 patients promotes increasing adaptation of the virus to the human host [20] [21] [22] . Indeed, mutations in SARS-CoV-2 spike glycoprotein have resulted in vastly increased transmissibility, infectivity and viral load in humans [6, 7, [23] [24] [25] . Now, a year into the pandemic, we observe multiple new, predominantly spike protein variants, with superior transmissibility that are changing the dynamics of the pandemic.

Currently leading in prevalence, in Europe and Israel, are the spike mutation variants UK 20I/501Y.V1 (also known as B.1.1.7) and South African 20H/501Y.V2 (also known as B.1.351) [26] [27] [28] (https://virological.org/t/mutations-arising-in-sars-cov-2-spike-onsustained-human-to-human-transmission-and-human-to-animal-passage/578 ). The UK variant has eight non-synonymous mutations and deletions located in the spike gene (https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sarscov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563). Among these changes are those that significantly affect the binding process to the host cell: N501Y in the receptor-binding domain (RBD), which increases binding affinity to ACE2 [29] and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint P681H in the S1-S2 furin cleavage site, which was shown to promote entry into respiratory epithelial cells and transmission in animal models ( Figure 1 ). The South African variant is characterized by eight mutations in the spike protein, including three at critical residues, K417N, E484K, and N501Y, of the RBD [26] . Apparently, these mutations evolved independently in a recently described, Brazilian P.1 (also known as B.1.1.28) variant (https://virological.org/t/genomic-characterisation-of-an-emergentsars-cov-2-lineage-in-manaus-preliminary-findings/586 ). Notably, the E484K mutation of these variant has been associated with reduced potency of anti-spike neutralizing antibodies [30] . The joint appearance of multiple spike mutations increases concern that new super-spreading variants are on the rise.

The spike protein is the target of SARS-CoV-2 neutralizing antibodies of which over 90 percent target its receptor binding domain (RBD) [31] . Therefore, the SARS-CoV-2 spike glycoprotein has been selected as the primary target of vaccines [32] and anti-viral drugs [10] . Consequently, every new mutation in the spike gene is a potential threat to vaccine and drug efficacy. Clearly, the spike protein's crucial part in both infectivity and neutralization, and its high tendency to mutate make it the most important sequencing target for monitoring circulating viruses.

Affirming the notion that prompt identification of new variants via genome sequencing is key to outbreak control; emergency public health sequencing initiatives were launched worldwide. The CDC SPHERES (SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance) program in the US and its ECDC parallel in Europe (European Centre for Disease Prevention and Control. Sequencing of SARS-CoV-2) as well as the COVID-19 Genomics Consortium UK (CoG-UK, https://www.cogconsortium.uk/ ) are leading examples. A US group has reported monitoring the GISAID (http://www.gisaid.org/) repository database of worldwide SARS-CoV-2 genomic sequences for mutations in the spike gene, associated with frequency shifts at regional and global levels (https://cov.lanl.gov/ ), [6] . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) In this work, we present HiSpike, a simple, high-throughput and cost efficient, 3-step targeted NGS method for full sequencing of the spike encoding gene of SARS-CoV-2.

HiSpike can be readily adapted to the workflow of standard laboratories engaged in sequencing. We demonstrate that HiSpike provides results per the spike gene identical to results obtained using the protocol for whole genome sequencing of SARS-CoV-2, which was developed by the ARTIC consortium (https://artic.network/ncov-2019). We show that HiSpike reliably detects major clade defining mutations in the spike gene such as the UK 20I/501Y.V1 and the South Africa 20H/501Y.V2 variants. While the ARTIC protocol is an expensive, labor-intensive process, commonly (for Illumina users) requires 4-5 days, the HiSpike method is easily implemented, and obtains sequences in less than 2 days and at a fraction of the cost. Taking into consideration that HiSpike is used for the spike gene only (12.8% of the complete genome), many more samples can be sequenced simultaneously, thus leading to significantly increased capacity.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

With the objective to detect on a national scale the clinical and public health SARS-CoV-2 variants of high concern, we set out to assemble a sequencing protocol with the following guidelines: The protocol must be high throughput, accessible to standard laboratories that engage in sequencing, inexpensive, simple, and with a short turnaround time. Because all current and likely future SARS-CoV-2 variants of high concern are based on spike gene mutations ( Figure 1 ) we focused the sequencing to this region. To achieve this goal, the HiSpike method for high throughput sequencing of the SARS-CoV-2 spike gene was developed. In this method, nucleic acid (NA) samples were converted to spike libraries for sequencing on a MiSeq (Illumina) instrument, which is among the most common NGS sequencing platforms used worldwide. The HiSpike method can generate sequence data from NA samples within 30 hours and involves three simple steps: two consecutive reactions, RT-PCR1 and PCR2, and a single cleanup step of the pooled MiSeq library (Figures 2A and B) . The RT-PCR1 converts the viral spike . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint RNA to cDNA, which is amplified using tailed primers to produce spike amplicons with forward and reverse universal tails ( Figure 2B ). The spike annealing sites of these primers were primarily derived from the established ARTIC V3 primers for tiling amplicons along the SARS-CoV-2 genome. Likewise, the RT-PCR1 was conducted in two multiplexed reactions to produce two overlapping sets of ~400 bp spike gene amplicons enclosed by forward and reverse universal tails. These amplicons were combined and subjected to PCR2, which added unique dual indexes and the Illumina P5 and P7 flow cell adaptors to each sample ( Figure 2B ). A series of experiments were initially done to optimize and simplify reaction conditions, primer properties, and enzymatic settings to robustly produce high quality libraries of the HiSpike method (data not shown). The optimized RT-PCR1 conditions eliminated the need for equilibration between samples due to the limited primer levels (0.045 µM) that . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint were maxed out during the 45 PCR cycles. Consequently, similar dsDNA amplicon levels in each sample were found and roughly maintained throughout the sequencing process (An example of a MiSeq sample read distribution is shown in Supplementary file S1). In this study, all HiSpike libraries were sequenced with MiSeq's smallest and fastest flow cell the V2 Nano kit. In a typical 250-bp paired-end run, we obtained about 2 million reads and could simultaneously sequence 96 samples.

To assess the sequencing performance of the HiSpike method, we compared its . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint Figure 3 . Spike gene sequence comparison between ARTIC and HiSpike. Sequences of 70 samples (with > 90% spike sequence coverage in both ARTIC and HiSpike methods) were compared using a heat-map. Grey shades between white and black indicate 0 to 10 SNPs respectively. HiSpike sequences were aligned based on an hierarchical clustering tree (shown to the right) vertically and the ARTIC sequences of the same samples were aligned horizontally. Pairs of the same sample are represented in the diagonal line (outlined in red).

The validated HiSpike sequencing capacities and short turnaround time from NA to sequence led to the selection of this method for nationally urgent sequence assignments of positive COVID-19 cases. These included travelers arriving from countries with a high incidence of spike variants of concern, instances of reinfection, severely ill patients, and hospitalized pregnant women. A total of 304 clinical NA samples arrived on five different occasions during two critical weeks in January (Jan. 14 to 28, 2021). During this time, a global spread of high concern variants (e.g. UK, South African, and Brazilian P.1) forced lockdowns in many countries including Israel, while . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ranging from 11 to 40 were analyzed. The median coverage of samples were as follows: Figure 5A ). Notably, samples in this study were collected form several clinical laboratories that use various extraction systems and SARS-CoV-2 determination methods. In rare cases, we observed low coverage in samples with Cts below 25 ( Figure   5A ) which likely represent poor quality or degraded NA that in our experience are also apparent when using the ARTIC method.

We next assessed the average coverage depth along the spike gene with relation to its Ct. This parameter is important because it provides insights into the coverage expectancy along the spike sequence. As seen in Figure 5B , the average coverage depth along the spike gene varied. While at Cts of 25 -30, the average coverage depth was more than 100 at Cts above 30, there was a significant decline and more regions remained below the five independent reads cut off ( Figure 5B) . Notably, key parts of the RBD in the spike gene were amplified and sequenced at coverage of 5 reads or more even in samples with high Cts (over 30), allowing detection of mutations like N501Y ( Figure 5B , RBD red bar).

We conclude that the HiSpike method is highly robust and suitable for full spike gene sequencing of samples with Cts up to 30. This is remarkably similar to the specifications of all other ARTIC based sequencing methods for SARS-CoV-2 [33] . Importantly, key regions in the spike gene will likely be detected also in samples with very low virus content.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Primers used in this study were manufactured by metabion or IDT and are shown in Supplementary files S3 and S4.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Products of PCR2 were pooled by collecting 4 µL from each well. The pooled library was CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint Reagent Kit v3 (600-cycle, Cat. # MS-102-3003) and a paired end 151X2 program was set.

Trimmomatic-0.36 was used for quality trimming of the raw read sequences, by clipping Here we show that HiSpike is a much simpler method than any currently published method, that: 1) requires (similar to original ARTIC version) only two pools per sample, 2) generates cDNA and target amplification in a single RT-PCR1 step, and 3) does not require library normalization because it is achieved by substantial consumption of the limited levels of PCR1 primers. HiSpike is also flexible, as it requires reagents that are . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Recently, spike protein multi-mutation variants have appeared with high transmissibility and potential resistance to neutralization by either convalescent or vaccine-elicited sera.

The current record high infection rates coupled with massive vaccination campaigns are expected to give rise to emergence of additional spike variants. Therefore, it is important to have a tool for rapid and high-throughput sequencing. The ARTIC whole genome sequencing methods are effective for high definition epidemiologic purposes in which short time to sequence and high volume is not the primary desire. Although the ARTIC sequencing method when performed using the nanopore technique (ARTIC's original platform) can achieve sample to sequence in less than 24 hours it is not highthroughput and its high price per sample is prohibitive for many standard laboratories.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint HiSpike can fill in the need for vast sequencing to cover a national scale of all SARS-CoV-2 positive samples: it is simple to execute, high-throughput and an inexpensive method that produces near real-time results.

Because our method requires less reads per sample, it also saves expensive storage space and computation resources for analysis. Essential web platforms like GISAID (https://www.gisaid.org/) allow submission of complete or nearly complete genomes, while they also perform multiple analyses that are focused on the spike gene such as the spike glycoprotein mutation surveillance. However, a most needed spike dedicated database for sequence deposit and global sharing for comparison and variant alerts has yet to be establish.

We have enumerated the many strengths of HiSpike; its desirable features and benefits that make it simple, rapid, high-throughput, affordable, and a key tool to assist formulating public health policy. Nevertheless, HiSpike does have some limitations, chief among them being that it does not sequence genomic regions outside the spike gene, which are covered by other protocols for whole genome sequencing [33, [35] [36] [37] . Rarely, mutations outside the spike gene can influence transmissibility. However, the most important aspect of this limitation is that molecular epidemiology including its uses for clade definition and outbreak profiling to aid contact tracing, is mostly effective at the whole genome level.

To the best of our knowledge, HiSpike is currently the only documented sequencing tool for specific monitoring of spike mutations. To ease transitions to the HiSpike method, we included a detailed user instruction manual (Supplementary file S2). We propose using HiSpike for routine sequencing of positive SARS-CoV-2 samples for near real-time monitoring of emerging spike mutations. In this manner, public health resources can help contain potential super spreading or vaccine-escape variants, even before these variants cause frequency shifts at the local, regional, or global levels.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All authors read and approved the final manuscript.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.03.02.21252290 doi: medRxiv preprint

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Geographic and Genomic Distribution of SARS-CoV-2 Mutations

Genomic sequencing effort for SARS-CoV-2 by country during the pandemic

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Interaction between heptad repeat 1 and 2 regions in spike protein of SARSassociated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Mutations in membrane-fusion subunit of spike glycoprotein play crucial role in the recent outbreak of COVID-19

Boshier FAT et al: Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

Structure and binding properties of Pangolin-CoV spike glycoprotein inform the evolution of SARS-CoV-2

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Evidence for hostdependent RNA editing in the transcriptome of SARS-CoV-2

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo

A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways

Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Emergence of a new SARS-CoV-2 variant in the UK

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Covid-19: The E484K mutation and the risks it poses

Adaptive immunity to SARS-CoV-2 and COVID-19

Krammer F: SARS-CoV-2 vaccines in development

A rapid, cost-effective tailed amplicon method for sequencing SARS-CoV-2

Comprehensive Analyses of SARS-CoV-2 Transmission in a Public Health Virology Laboratory

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes

A high-throughput strategy for COVID-19 testing based on nextgeneration sequencing

Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR

Supplementary file S1. Percentage of clusters passing filter (PF) for 92 samples of a MiSeq (Illumina) run. The Red column represents the average PF reads/sample.